Seres Therapeutics (MCRB) Says It's 'Extremely Pleased' with Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis
Tweet Send to a Friend
Seres Therapeutics, Inc., (NASDAQ: MCRB) today announced positive topline results from a SER-287 Phase 1b placebo-controlled induction study in 58 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
